Jove
Visualize
Contact Us

Related Experiment Videos

Spurious polycythemia.

N J Weinreb, C F Shih

    Seminars in Hematology
    |October 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Spurious polycythemia is not a disease but can indicate abnormal plasma volume. Management should focus on nonhematologic factors like hypertension, not red blood cell reduction.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.

    Molecular genetics and metabolism·2009
    Same author

    Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study.

    Clinical genetics·2008
    Same author

    The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.

    Clinical genetics·2007
    Same author

    Skeletal aspects of Gaucher disease: a review.

    The British journal of radiology·2002
    Same author

    Response of Gaucher bone disease to enzyme replacement therapy.

    The British journal of radiology·2002
    Same author

    Interruption in enzyme replacement therapy for Gaucher disease.

    British journal of haematology·2001
    Same journal

    Pain in SCD-Many mechanisms and mysteries.

    Seminars in hematology·2026
    Same journal

    The many facets of cardiopulmonary complications in sickle cell disease.

    Seminars in hematology·2026
    Same journal

    Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

    Seminars in hematology·2026
    Same journal

    Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

    Seminars in hematology·2026
    Same journal

    Telomeres biology disorders: the past, the present and the future.

    Seminars in hematology·2026
    Same journal

    Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

    Seminars in hematology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Hematology
    • Internal Medicine
    • Cardiovascular Medicine

    Background:

    • Spurious polycythemia is a condition characterized by an elevated hematocrit.
    • It is not a primary disease but can stem from physiological states or plasma volume abnormalities.

    Observation:

    • The degree of hematocrit elevation does not correlate with patient morbidity.
    • There is no evidence of abnormal erythroid proliferation in spurious polycythemia.

    Findings:

    • Differentiation between physiological states and plasma volume abnormalities may have prognostic value.
    • Nonhematologic factors, especially hypertension, are significant contributors to cardiovascular morbidity.

    Implications:

    • Reducing red blood cell volume through phlebotomy or myelosuppression is inappropriate.
    • Aggressive management of nonhematologic parameters like hypertension is crucial for reducing cardiovascular risks.